Innovative Approaches in the Management of Metastatic Breast Cancer: Managed Care Considerations on the Evolving Role of Targeted Therapy
English
Recorded Courses
hosted by National Association of Managed Care Physicians (NAMCP)
hosted by National Association of Managed Care Physicians (NAMCP)
attend it anywhere online
category
Medicine, Nursing, Healthcare Management
Oncology
price
On Book
Innovative Approaches in the Management of Metastatic Breast Cancer: Managed Care Considerations on the Evolving Role of Targeted Therapy is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States in 2022. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of the disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes. With these options becoming available for the treatment of metastatic breast cancer, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on the changing treatment paradigm, with the ultimate goal of improving patient outcomes.,Upon completion of this activity, participants will be able to:,• Examine the clinical and economic burden of metastatic breast cancer in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations,• Compare and contrast efficacy and safety profiles and recent clinical data of current and emerging targeted therapies, including PARP, PI3K, and CDK4/6 inhibitors, for the treatment of advanced breast cancer,• Explore the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth,• Review the mechanistic rationale concerning the role of targeted therapies, including PARP, PI3K, and CDK4/6 inhibition, in metastatic breast cancer,• Compare and contrast adverse events associated with targeted therapies in order to maximize tolerability and adherence to therapeutic regimens,• Assess methods to enable optimal cost management of targeted therapies to be realized by multiple metastatic breast cancer stakeholders including managed care organizations